Organon (OGN) Net Cash Flow (2020 - 2026)
Organon (OGN) recorded quarterly Net Cash Flow of $573.0 million in Q1 2026, up 616.22% quarter-over-quarter from -$111.0 million in Q4 2025, and up 433.14% on a YoY basis from $107.5 million in Q1 2025.
Organon (OGN) Net Cash Flow (2020 - 2026) Analysis & Trends
Organon's Net Cash Flow history runs 7 years deep, the most recent figure standing at $573.0 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 433.14% year-over-year to $573.0 million; the TTM figure through Mar 2026 stood at $494.0 million (up 2570.0% YoY), while the FY2025 annual figure was -$251.0 million, down 532.76% from the prior year.
- Net Cash Flow was $573.0 million for Q1 2026 at Organon, up from -$111.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $573.0 million in Q1 2026 to a low of -$266.0 million in Q1 2023.
- Historically, Net Cash Flow has averaged $20.9 million across 5 years, with a median of -$12.0 million in 2024.
- Biggest YoY gain for Net Cash Flow was 708.33% in 2025; the steepest drop was 1025.0% in 2025.
- A 5-year view of Net Cash Flow shows it stood at $124.0 million in 2022, then soared by 92.74% to $239.0 million in 2023, then plunged by 94.98% to $12.0 million in 2024, then slumped by 1025.0% to -$111.0 million in 2025, then jumped by 616.22% to $573.0 million in 2026.
- The last three Net Cash Flow figures came in at $573.0 million (Q1 2026), -$111.0 million (Q4 2025), and $73.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | 210.32 Mn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | -2.05 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 4.17 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | -587.00 Mn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 573.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 573.00 Mn |
| Mar 31, 2026 | 573.00 Mn |
| Dec 31, 2025 | -111.00 Mn |
| Dec 31, 2025 | -111.00 Mn |
| Sep 30, 2025 | 73.00 Mn |
| Sep 30, 2025 | 73.00 Mn |
| Jun 30, 2025 | -41.00 Mn |
| Jun 30, 2025 | -41.00 Mn |
| Mar 31, 2025 | -172.00 Mn |
| Mar 31, 2025 | -172.00 Mn |
| Dec 31, 2024 | 12.00 Mn |
| Dec 31, 2024 | 12.00 Mn |
| Sep 30, 2024 | -12.00 Mn |
| Sep 30, 2024 | -12.00 Mn |
| Jun 30, 2024 | 152.00 Mn |
| Jun 30, 2024 | 152.00 Mn |
| Mar 31, 2024 | -94.00 Mn |
| Mar 31, 2024 | -94.00 Mn |
| Dec 31, 2023 | 239.00 Mn |
| Dec 31, 2023 | 239.00 Mn |